Key Takeaways
- Puma Biotechnology reported a $3.8 million loss in Q1, equivalent to 7 cents per share.
- Revenue for the quarter reached $44.8 million, with expectations of $52-$55 million in Q2.
- Full-year revenue projections are between $222 million and $229 million.
Financial Performance Overview
Puma Biotechnology Inc. (PBYI), based in Los Angeles, announced a loss of $3.8 million for the first quarter of the fiscal year. This loss translates to 7 cents per share, while the adjusted loss—accounting for stock option expenses—is reported at 4 cents per share.
Despite the loss, the biopharmaceutical company achieved a revenue of $44.8 million during the quarter. Looking ahead, Puma expects to generate between $52 million and $55 million in the upcoming quarter ending in June. Additionally, the company’s full-year revenue guidance is set within the range of $222 million to $229 million.
These financial metrics reflect Puma Biotechnology’s ongoing efforts within the biopharmaceutical industry, underscoring both current challenges and future revenue aspirations.
The content above is a summary. For more details, see the source article.